Pyrotinib and Capecitabine Combo Improved PFS Compared to Lapatinib Plus Capecitabine for HER2-Positive Breast Cancer

Published by W Butcher on

The combination of pyrotinib plus capecitabine resulted in a statistically significant improvement in progression-free survival compared with lapatinib (Tykerb) plus capecitabine as treatment of patients with previously treated HER2-positive metastatic breast cancer, according to data published in The Lancet Oncology. The pyrotinib-plus-capecitabine combination also maintained a tolerable safety profile, presenting itself as an alternative treatment option for this cohort of patients after trastuzumab (Herceptin) and chemotherapy. “The findings from this study suggest that pyrotinib plus capecitabine is a novel treatment for patients with HER2-positive metastatic breast cancer after trastuzumab and chemotherapy, and is an alternative option to the current treatment landscape, particularly in regions with scarce access to HER2-directed drugs,” wrote the investigators.

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.